Table 2.

Changes in dd-cfDNA post-biopsy by type of rejection

Group1-Month Follow-up2–3-Month Follow-up
N Month 0, Median (25th, 75th), %Month 1, Median (25th, 75th), % P N Month 0, Median (25th, 75th), %Month 2–3, Median (25th, 75th), % P
BPAR or treated rejection210.62 (0.26, 1.23)0.35 (0.23, 0.96)0.34230.77 (0.23, 2.91)0.21 (0.11, 0.63)0.002
Clinical (no BPAR)100.31 (0.25, 0.60)0.29 (0.22, 0.41)0.3880.38 (0.23, 1.26)0.17 (0.14, 0.26)0.31
ABMR61.61 (1.02, 3.28)1.20 (0.50, 4.94)>0.9963.85 (2.54, 6.10)1.32 (0.42, 3.87)0.09
TCMR51.13 (0.26, 1.23)0.37 (0.31, 1.35)0.6390.25 (0.21, 0.77)0.12 (0.06, 0.23)0.004
No BPAR or treated rejection210.23 (0.11, 0.41)0.18 (0.08, 0.24)0.10260.33 (0.12, 0.57)0.17 (0.06, 0.28)0.003
Control360.37 (0.21, 0.51)0.25 (0.17, 0.52)0.27620.24 (0.12, 0.42)0.15 (0.08, 0.23)0.004
  • The study groups are listed in the first column. For each group, distribution of dd-cfDNA at time of biopsy, at first test at 1 mo, and after 2–3 mo is given, along with the number of patients in each group with a dd-cfDNA measurement at that time point. Finally, a P value is given, showing whether dd-cfDNA exhibits a statistically significant change from time of biopsy to follow-up time for two different follow-up times: at 1 mo and at 2–3 mo. dd-cfDNA, donor-derived cell-free DNA; BPAR, biopsy–proven acute rejection; ABMR, antibody-mediated rejection; TCMR, T cell–mediated rejection.